# A Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GSK2140944 in the Treatment of Uncomplicated Urogenital Gonorrhea Caused by Neisseria Gonorrhoeae

> **NCT02294682** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 106 (actual)

## Conditions studied

- Gonorrhea

## Interventions

- **DRUG:** GSK2140944

## Key facts

- **NCT ID:** NCT02294682
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04-15
- **Primary completion:** 2016-07-01
- **Final completion:** 2016-07-27
- **Target enrollment:** 106 (ACTUAL)
- **Last updated:** 2017-05-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02294682

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02294682, "A Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GSK2140944 in the Treatment of Uncomplicated Urogenital Gonorrhea Caused by Neisseria Gonorrhoeae". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02294682. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*